The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Viridian Therapeutics Inc is $35.00, about 66.1% above its August 5 closing price of $21.07
Drivers of the quarter
LUMVOA LAUNCH - Company said Lumvoa launch drove higher SG&A expenses and strong early physician engagement
R&D EXPENSES - Company said Q2 R&D expenses fell due to reduced costs for veligrotug and elegrobart studies, partly offset by investment in TSHR program and higher personnel costs
Q2 results and cash position
U.S. biotech firm's Q2 net loss widened year over year as Lumvoa launch drove higher SG&A costs
VRDN•
